Profile data is unavailable for this security.
About the company
BioAge Labs, Inc. is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its lead product candidate, azelaprag, is an orally available small molecule agonist of the apelin receptor (APJ) that was observed to promote metabolism and prevent muscle atrophy during bed rest in a Phase Ib clinical trial. It has initiated a Phase II trial of azelaprag in combination with tirzepatide for the treatment of obesity in older adults. Azelaprag has the potential as an oral regimen to reduce weight loss and improve body composition in patients on obesity therapy with incretin drugs. It is also developing orally available small molecule brain penetrant NLRP3 inhibitors for the treatment of diseases driven by neuroinflammation. Its preclinical programs, based on novel insights from the Company’s discovery platform built on human longevity data, address key pathways in metabolic aging.
- Revenue in USD (TTM)0.00
- Net income in USD-62.16m
- Incorporated2015
- Employees58.00
- LocationBIOAGE Labs Inc1445A South 50Th StreetRICHMOND 94804United StatesUSA
- Phone+1 (510) 806-1445
- Websitehttps://bioagelabs.com
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Olema Pharmaceuticals Inc | 0.00 | -109.63m | 657.42m | 80.00 | -- | 2.89 | -- | -- | -2.06 | -2.06 | 0.00 | 3.97 | 0.00 | -- | -- | 0.00 | -50.73 | -30.06 | -56.10 | -31.40 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 7.76 | -- | -- | -- |
| IGM Biosciences Inc | 2.92m | -219.84m | 661.40m | 198.00 | -- | 8.40 | -- | 226.66 | -3.65 | -3.65 | 0.0484 | 1.33 | 0.0075 | -- | -- | 13,026.79 | -56.45 | -44.66 | -63.54 | -48.20 | -- | -- | -7,534.03 | -23,668.96 | -- | -- | 0.00 | -- | 99.25 | -- | -11.45 | -- | 73.48 | -- |
| Humacyte Inc | 0.00 | -152.87m | 667.66m | 183.00 | -- | -- | -- | -- | -1.34 | -1.34 | 0.00 | -0.5317 | 0.00 | -- | -- | 0.00 | -115.74 | -- | -134.05 | -- | -- | -- | -- | -- | -- | -27.44 | -- | -- | -100.00 | -- | -825.83 | -- | -- | -- |
| Perspective Therapeutics Inc | -1.87m | -49.02m | 669.56m | 116.00 | -- | 1.96 | -- | -- | -1.39 | -1.75 | -0.0437 | 5.06 | -0.0074 | -- | -- | -16,086.21 | -19.37 | -- | -20.14 | -- | -- | -- | -- | -- | -- | -- | 0.005 | -- | -- | -- | -- | -- | -- | -- |
| Tourmaline Bio Inc | 0.00 | -48.85m | 673.34m | 44.00 | -- | 2.10 | -- | -- | -1.68 | -1.68 | 0.00 | 12.52 | 0.00 | -- | -- | 0.00 | -20.37 | -- | -21.05 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 42.99 | -- | -- | -- |
| Altimmune Inc | 409.00k | -101.35m | 676.60m | 59.00 | -- | 4.43 | -- | 1,654.27 | -1.62 | -1.62 | 0.0064 | 2.15 | 0.0023 | -- | 1.46 | 6,932.20 | -56.83 | -39.62 | -61.41 | -42.58 | -- | -- | -24,778.97 | -1,811.89 | -- | -- | 0.00 | -- | 726.47 | -47.15 | -4.41 | -- | -45.92 | -- |
| Ironwood Pharmaceuticals, Inc. | 378.42m | -2.46m | 687.68m | 267.00 | -- | -- | -- | 1.82 | -0.016 | -0.016 | 2.39 | -1.95 | 0.8284 | -- | 3.77 | 1,417,296.00 | -0.6832 | -4.54 | -1.07 | -5.20 | -- | -- | -0.8248 | -7.81 | -- | 3.88 | 2.08 | -- | 7.83 | 5.02 | -672.50 | -- | 160.10 | -- |
| Tectonic Therapeutic Inc | 0.00 | -58.25m | 688.69m | 13.00 | -- | 4.14 | -- | -- | -18.52 | -18.52 | 0.00 | 11.29 | 0.00 | -- | -- | 0.00 | -35.55 | -45.22 | -40.16 | -49.14 | -- | -- | -- | -- | -- | -128.75 | 0.0066 | -- | -- | -- | 111.48 | -- | -66.27 | -- |
| BIOAGE Labs Inc | 0.00 | -62.16m | 689.15m | 58.00 | -- | -- | -- | -- | -1.82 | -1.82 | 0.00 | 4.26 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -4.99 | 0.0724 | -- | -- | -- | -60.75 | -- | -- | -- |
| Arbutus Biopharma Corp | 6.74m | -76.70m | 691.64m | 73.00 | -- | 6.47 | -- | 102.59 | -0.4259 | -0.4259 | 0.0374 | 0.5643 | 0.0451 | -- | 3.57 | 92,356.16 | -51.29 | -52.62 | -59.50 | -58.11 | -- | -- | -1,137.65 | -537.81 | -- | -- | 0.00 | -- | -53.51 | 25.00 | -4.89 | -- | -2.40 | -- |
| Annexon Inc | 0.00 | -115.16m | 692.03m | 71.00 | -- | 1.91 | -- | -- | -1.22 | -1.22 | 0.00 | 3.42 | 0.00 | -- | -- | 0.00 | -36.04 | -44.06 | -38.13 | -46.93 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 5.43 | -- | 62.56 | -- |
| MBX Biosciences Inc | -100.00bn | -100.00bn | 696.75m | 36.00 | -- | 2.56 | -- | -- | -- | -- | -- | 8.13 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -24.60 | -- | -- | -- |
| Silence Therapeutics plc | 22.74m | -50.94m | 711.10m | 115.00 | -- | 5.69 | -- | 31.27 | -0.4095 | -0.4095 | 0.1816 | 1.02 | 0.1273 | -- | 2.56 | 197,734.90 | -28.51 | -43.60 | -32.89 | -54.91 | 56.40 | -- | -224.01 | -287.30 | -- | -- | 0.0016 | -- | 44.99 | -- | -6.86 | -- | 156.10 | -- |
| Immunome Inc | 10.78m | -262.59m | 721.88m | 55.00 | -- | 2.74 | -- | 66.94 | -5.64 | -5.64 | 0.2591 | 4.23 | 0.0639 | -- | -- | 196,072.70 | -155.54 | -94.54 | -193.54 | -112.66 | -- | -- | -2,435.02 | -1,403.15 | -- | -- | 0.00 | -- | -- | -- | -184.68 | -- | 29.52 | -- |
| ORIC Pharmaceuticals Inc | 0.00 | -110.78m | 724.47m | 107.00 | -- | 2.30 | -- | -- | -1.76 | -1.76 | 0.00 | 4.47 | 0.00 | -- | -- | 0.00 | -35.69 | -33.92 | -37.77 | -35.77 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -12.99 | -- | 10.09 | -- |
Data as of Nov 13 2024. Currency figures normalised to BIOAGE Labs Inc's reporting currency: US Dollar USD
17.13%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Cormorant Asset Management LPas of 27 Sep 2024 | 2.81m | 8.22% |
| RA Capital Management LPas of 27 Sep 2024 | 2.21m | 6.47% |
| Emerald Advisers LLCas of 30 Sep 2024 | 281.32k | 0.82% |
| Emerald Mutual Fund Advisers Trustas of 30 Sep 2024 | 229.43k | 0.67% |
| JPMorgan Investment Management, Inc.as of 30 Sep 2024 | 189.25k | 0.55% |
| TD Asset Management, Inc.as of 30 Sep 2024 | 59.68k | 0.18% |
| Platinum Investment Management Ltd.as of 30 Sep 2024 | 50.00k | 0.15% |
| Landscape Capital Management LLCas of 30 Sep 2024 | 12.64k | 0.04% |
| JPMorgan Chase Bank, NA (Investment Management)as of 30 Sep 2024 | 10.75k | 0.03% |
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
